Literature DB >> 15638855

Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival.

Niels Frost Andersen1, Therese Standal, Johan Lanng Nielsen, Lene Heickendorff, Magne Borset, Flemming Brandt Sørensen, Niels Abildgaard.   

Abstract

Angiogenesis is a complex process involved in the proliferation and metastasis of malignant tumours, and partly triggered by the secretion of various angiogenic factors by tumour cells or cells in the stromal environment. We investigated the correlation between bone marrow angiogenesis, estimated as microvessel density (MVD), and interleukin-6 (IL-6), basic fibroblastic growth factor (bFGF), hepatocyte growth factor (HGF) and syndecan-1 in 67 patients with newly diagnosed multiple myeloma, and evaluated the prognostic value of these parameters. Circulating levels of IL-6, bFGF, HGF and syndecan-1 were significantly higher in patients than in controls. Moreover, in patients, bone marrow levels of bFGF, HGF and syndecan-1 were higher than peripheral blood levels. Positive correlations were found between MVD and syndecan-1 blood levels (r = 0.33, P = 0.017), syndecan-1 bone marrow levels (r = 0.49, P = 0.046) and HGF blood levels (r = 0.36, P = 0.008) respectively. High MVD and high blood levels of IL-6, HGF and syndecan-1 were predictive of a shorter survival. In a multivariate survival analysis MVD and blood levels of IL-6 retained independent prognostic significance, while in a survival analysis without MVD the peripheral blood levels of HGF and syndecan-1 were strong independent prognostic factors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15638855     DOI: 10.1111/j.1365-2141.2004.05299.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  33 in total

Review 1.  Pathogenesis beyond the cancer clone(s) in multiple myeloma.

Authors:  Giada Bianchi; Nikhil C Munshi
Journal:  Blood       Date:  2015-04-02       Impact factor: 22.113

2.  Serglycin proteoglycan is required for multiple myeloma cell adhesion, in vivo growth, and vascularization.

Authors:  Anurag Purushothaman; Bryan P Toole
Journal:  J Biol Chem       Date:  2014-01-08       Impact factor: 5.157

3.  Angiogenesis and multiple myeloma.

Authors:  Nicola Giuliani; Paola Storti; Marina Bolzoni; Benedetta Dalla Palma; Sabrina Bonomini
Journal:  Cancer Microenviron       Date:  2011-07-07

Review 4.  Insights into the molecular roles of heparan sulfate proteoglycans (HSPGs-syndecans) in autocrine and paracrine growth factor signaling in the pathogenesis of Hodgkin's lymphoma.

Authors:  Rajendra Gharbaran
Journal:  Tumour Biol       Date:  2016-06-18

5.  Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphisms.

Authors:  Tristan M Sissung; Cody J Peer; Neha Korde; Sham Mailankody; Dickran Kazandjian; David J Venzon; Ola Landgren; William D Figg
Journal:  Cancer Chemother Pharmacol       Date:  2017-05-09       Impact factor: 3.333

Review 6.  Non-anticoagulant heparins and inhibition of cancer.

Authors:  Benito Casu; Israel Vlodavsky; Ralph D Sanderson
Journal:  Pathophysiol Haemost Thromb       Date:  2009-01-27

7.  Tissue factor regulation by epidermal growth factor receptor and epithelial-to-mesenchymal transitions: effect on tumor initiation and angiogenesis.

Authors:  Chloe C Milsom; Joanne L Yu; Nigel Mackman; Johann Micallef; G Mark Anderson; Abhijit Guha; Janusz W Rak
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

8.  Bone marrow angiogenesis in myeloma and its precursor disease: a prospective clinical trial.

Authors:  M Bhutani; B Turkbey; E Tan; T J Kemp; L A Pinto; A R Berg; N Korde; A R Minter; B M Weiss; E Mena; L Lindenberg; O Aras; M P Purdue; J N Hofmann; S M Steinberg; K R Calvo; P L Choyke; I Maric; K Kurdziel; O Landgren
Journal:  Leukemia       Date:  2013-09-18       Impact factor: 11.528

9.  The relationship between soluble receptor of interleukin-6 with angiogenic cytokines and proliferation markers in multiple myeloma.

Authors:  George Tsirakis; Constantina A Pappa; Maria Kaparou; Anna Boula; Vaitsa Katsomitrou; Athina Xekalou; Stavroula Kyriakaki; Michael G Alexandrakis
Journal:  Tumour Biol       Date:  2012-12-16

10.  Tumor cell gene expression changes following short-term in vivo exposure to single agent chemotherapeutics are related to survival in multiple myeloma.

Authors:  Bart Burington; Bart Barlogie; Fenghuang Zhan; John Crowley; John D Shaughnessy
Journal:  Clin Cancer Res       Date:  2008-08-01       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.